Clinical findings suggest that activation of KCNQ2 channels may provide treatment options for other types of neurological disorders including rare forms of epilepsy. Under the agreement, Neuro3 will receive a worldwide license for intellectual property covering t...
By joining forces, these organizations are not only advancing research and treatment options but also demonstrating the strength and impact of collective action in the fight against Developmental Epileptic Encephalopathies (DEEs). This initiative promises to significantly improve clinical outcomes and ...
S. K+ Channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem. Rev. 108, 1744–1773 (2008). CAS PubMed PubMed Central Google Scholar Wulff, H., Castle, N. A. & Pardo, L. A. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug ...
Since these forms of epilepsy can now be detected earlier (i.e., before symptoms appear) and more definitively, better treatment options will be available in those individuals identified as having BFNC, rolandic epilepsy or JME. The present invention is also directed to methods for screening for...
There is a significant unmet medical need that requires better treatment options. Parents/caregivers are confident in recognizing seizures and most have been trained by medical personnel using video electroencephalography-documented seizures.Cynthia Harden...
Masato Kasuga and colleagues and Shiro Maeda and colleagues each report the independent identification of SNPs in KCNQ1 associated with type 2 diabetes in the Japanese population. Each group replicated the associations in other populations of East Asian
Pharmacotherapy, implantable cardioverter-defibrillators, and left cardiac sympathetic denervation are part of the current treatment options, but no targeted therapy for LQTS exists to date. Previous studies indicate that induced autoimmunity against the voltage-gated KCNQ1 K channels accelerates cardiac ...